Inspire Announces Poster Presentations at the 2007 North American Cystic Fibrosis Conference
DURHAM, N.C.--(BUSINESS WIRE)--Oct 3, 2007 - Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that Inspire scientists, clinical investigators and collaborators will present information from four abstracts in poster presentations during the 21st Annual North American Cystic Fibrosis (NACF) Conference at the Anaheim Convention Center in California on October 3-6, 2007.Two of the four abstracts contain data from Inspire's Phase 2 clinical trials with denufosol for the treatment of cystic fibrosis: -0-
-- Analyzing Percent Change in Cystic Fibrosis Clinical Trials L. LaVange, J. Engels, F.J. Accurso Thursday, October 4, 2007, 11:30 a.m. - 1:50 p.m. Friday, October 5, 2007, 7:00 a.m. - 8:20 a.m.-0-
-- Pediatric Experience from Three Integrated Phase 2 Studies of Denufosol Tetrasodium Inhalation Solution D. Mathews, A. Schaberg, V. Brandi, J. Engels, J. Gorden, R. Deterding Thursday, October 4, 2007, 11:30 a.m. - 1:50 p.m. Friday, October 5, 2007, 7:00 a.m. - 8:20 a.m.
A third abstract contains data from surveys of investigators from TIGER-1, Inspire's first of two planned Phase 3 trials with denufosol: -0-
-- Patterns of Antibiotic Use for Patients with Mild Cystic Fibrosis J.Y. Friedman, C. Hardy, E.M. Dewitt, K.A. Schulman, S.D. Reed Thursday, October 4, 2007, 11:30 a.m. - 1:50 p.m. Friday, October 5, 2007, 4:30 p.m. - 6:30 p.m.
A fourth abstract is related to the mechanism of action of denufosol: -0-
-- Denufosol is a Stable and Potent Inducer of Airway Secretion W. Thelin, E. Lazarowski, J.L. Boyer, R. Boucher Thursday, October 4, 2007, 11:30 a.m. - 1:50 p.m. Friday, October 5, 2007, 4:30 p.m. - 6:30 p.m.
These posters can be downloaded from Inspire's website, www.inspirepharm.com, following the conclusion of the conference. Additional information related to the NACF Conference can be obtained at www.nacfconference.org.
About Inspire
Inspire is a biopharmaceutical company dedicated to discovering, developing and commercializing prescription pharmaceutical products in disease areas with significant commercial potential and unmet medical needs. Inspire employs a U.S. sales force for the promotion of AzaSite(TM) (azithromycin ophthalmic solution) 1% for bacterial conjunctivitis, Elestat(R) (epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis(R) (cyclosporine ophthalmic emulsion) 0.05% for dry eye. Inspire is focused on the therapeutic areas of ophthalmology and respiratory/allergy, and is developing products for dry eye, cystic fibrosis, allergic rhinitis and glaucoma. Elestat and Restasis are registered trademarks owned by Allergan, Inc. AzaSite is a trademark owned by InSite Vision Incorporated. For more information, visit www.inspirepharm.com.
Contact
Inspire Pharmaceuticals, Inc.
Investor Contact:
Jenny Kobin, VP, Investor Relations and
Corporate Communications, 919-941-9777, Ext. 219
or
Media Contact:
BMC Communications
Dan Budwick, 212-477-9007, Ext. 14
